Physician profile
Michael Cooperman
NPI 1972568244
$40,428.67
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $3,879 · 2021: $1,372 · 2022: $1,014.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33,000.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,235.69 | 2019-2020 | |
| Lilly USA, LLC | $1,192.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $966.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $555.16 | 2019-2022 | |
| Novo Nordisk INC | $515.08 | 2019-2022 | |
| Mannkind Corporation | $513.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.47 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $212.86 | 2020-2022 | |
| Corcept Therapeutics | $204.11 | 2020-2022 | |
| Abbvie INC. | $154.90 | 2019-2022 | |
| Abbott Laboratories | $112.31 | 2019-2022 | |
| Medtronic Minimed, INC. | $38.29 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.82 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $14.07 | 2019 | |
| Dexcom, INC. | $12.46 | 2022 | |
| Amneal Pharmaceuticals LLC | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.